A Randomized, Double-blind, Placebo Controlled, Multicenter, 3-period Crossover Study to Compare the Effect of Indacaterol (150microg o.d.) on Inspiratory Capacity to Placebo in Patients With Moderate COPD, Using Open Label Tiotropium (18microg o.d.) as Active Control.

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Multicenter, 3-period Crossover Study to Compare the Effect of Indacaterol (150microg o.d.) on Inspiratory Capacity to Placebo in Patients With Moderate COPD, Using Open Label Tiotropium (18microg o.d.) as Active Control.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2013

At a glance

  • Drugs Indacaterol (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics; Registrational
  • Acronyms INSPIRATION
  • Most Recent Events

    • 17 Feb 2012 Actual number of patients changed from to 125 to 173 as reported by ClinicalTrials.gov.
    • 31 Jan 2011 Actual end date changed from Jul 2010 to Jan 2011 as reported by ClinicalTrials.gov.
    • 31 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top